Hereditary amyloidosis: Some words on the history and present status of our eminent subject

M. Benson

DOI: https://doi.org/10.3109/13506120009146817

2000-01-01

Abstract:hile hereditary (familial) amyloidosis has probably been around for as long as recorded hisW tory, it has only been recognized as a distinct entity in the latter half of the 20h Century. The first documentation of transthyretin amyloidosis as an autosomal dominant inherited disease was in 1952 by Corino Andrade' . This disease which was named familial amyloidotic polyneuropathy (FAP) because of the predominance of peripheral neuropathy in affected individuals of Portuguese origin has grown in importance as the number of mutations in transthyretin which are associated with pathology (presently over 70) and the sytemic nature of the disease have become appreciated*. It is truly the prototype of the hereditary systemic amyloidoses and displays all of the characteristics of this group of fibril protein deposition diseases. 1) Amyloid affects many organ systems with variation fiom kindred to kindred and individual to individual. 2) The disease is adultonset; usually starting after the childbearing years, as would be expected for a fatal hereditary condition. 3) The disease is dominantly inherited, a common feature of diseases due to mutations in genes for structural proteins. 4)Anumber of mutations in the same protein may govern expression of the genetic disease. 5 ) The occurrence of amyloid deposition in old age in the absence of any genetic mutation. Transthyretin amyloidosis is only one of several forms of systemic amyloidosis that have been characterized in the last 20 years. Mutations in the gene for apolipoprotein AI cause a number of syndromes of systemic amyloidosis with restrictive cardiomyopathy the most prominent clinical feature, but with cutaneous and renal amyloidosis in some kindreds. As with transthyretin, a number of disease causing mutations of apoA 1 have been described; at least eight within the last ten years. Four mutations in the gene for fibrinogen Aa-chain are associated with renal amyloidosis. Two mutations in lysozyme have been associated with either renal or hepatic amyloidosis. Two mutations in gelsolin and one in cystatin C can cause systemic amyloid deposition. In the case of transthyretin and apolipoprotein AI, it is now known that normal protein can be associated with amyloid deposits; transthyretin in the heart, apoAI in the aorta. Whether amyloid deposits can be derived fiom normal fibrinogen Aa-chain, lysozyme, gelsolin or cystatin C has yet to be explored. Besides the hereditary systemic amyloid syndromes, several inherited forms of localized amyloidosis have been described. The most common is Alzheimer disease due to mutations in APPP, presenilin1 or presenilin-2. GertstmannStraussler-Scheinker disease and familial Cruetzfeld-Jacob diseases are due to mutations in the pnon protein. As with the systemic amyloidoses, several mutations have been found to cause the localized forms and, at least with Alzheimer disease, senile amyloid deposits fiom normal ApPP occur without obvious genetic basis. Despite the amazing amount of knowledge gained in the last two decades about these diseases, we still have little in the way of specific therapy to offer individuals and families affected with hereditary amyloidoses. We can offer DNA testing, genetic counseling and the reassurance that science is progressing at an incredible rate.